The latest in herpes simplex keratitis therapy;Actualités thérapeutiques de l'herpès cornéen

Journal Francais d'Ophtalmologie

Volumn 27, Issue 5, 2004, Pages 547-557

  Labetoulle, M ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Acyclovir; Antiviral; Herpes simplex virus; Keratitis; Prevention

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CEBEVIR; FAMCICLOVIR; IDOXURIDINE; IODODEOXYCYTIDINE; ORAVIR; STEROID; TRIFLURIDINE; VALACICLOVIR; VIDARABINE;

CORNEA TRANSPLANTATION; DISEASE SEVERITY; HERPES SIMPLEX KERATITIS; HIGH RISK POPULATION; HUMAN; RECURRENT DISEASE; RELAPSE; REVIEW; VACCINATION; VISUAL IMPAIRMENT;

EID: 3042543705     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(04)96178-5     Document Type: Review

References (103)

1. Liesegang TJ. Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol, 1989;107:1160-5.
2. Wilhelmus KR, Coster DJ, Donovan HC, Falcon MG, Jones BR. Prognosis indicators of herpetic keratitis. Analysis of a five-year observation period after corneal ulceration. Arch Ophthalmol, 1981;99:1578-82.
3. Legeais JM, Labetoulle M, Renard G, Gaillot D, Pouliquen Y. Indications des kératoplasties transfixiantes. Étude rétrospective de 2 962 cas sur onze ans. J Fr Ophtalmol, 1993;16:516-22.
4. Wilhelmus KR. The treatment of herpes simplex virus epithelial keratitis. Trans Am Ophthalmol Soc, 2000;98:505-32.
5. Colin J. Pathologies de la cornée et de la conjonctive. Atteintes herpétiques. Zona ophtalmique. In: Œil et virus, Offret H. Masson (Paris), 2000; p. 219-240.
6. Renard G, Denis J. Traitement des kératites herpétiques. J Fr Ophtalmol, 1991;14:353-62.
7. Colin J. Traitement actuel de l'herpès cornéen. J Fr Ophtalmol, 1986;9:671-8.
8. Denis J, Chouraqui P, Karpouzas I, Hoang-Xuan T, Pouliquen Y. Traitement des kératites herpétiques superficielles par la vidarabine (Vira A): étude multicentrique de 100 cas. J Fr Ophtalmol, 1990;13:143-50.
9. Gordon YJ. The evolution of antiviral therapy for external ocular viral infections over twenty-five years. Cornea, 2000;19:673-80.
10. Labetoulle M, Frau E. Chimiothérapie antivirale de l'herpès oculaire du sujet immunocompétent. Virologie, 2000;4:32-8.
11. Coster DJ, Jones BR, McGill JI. Treatement of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine. Br J Ophthalmol, 1979;63:418.
12. Poirier RH, Kingham JD, de Miranda P, Annel M. Intraocular antiviral penetration. Arch Ophthalmol, 1982;100:1964-7.
13. Agut H, Bodaghi B, Calvi P, Goldschmidt P, Huraux JM, Labetoulle M et al. Traitement des infections virales. In: Oeil et virus, Offret H. Masson (Paris), 2000; p. 85-134.
14. Colin J, Tournoux A, Chastel C, Renard G. Kératite herpétique superficielle. Traitement comparatif en double insu par aciclovir et idoxuridine. Nouv Presse Med, 1981;10:2969-75.
15. Collum LM, Benedict-Smith A, Hillary IB. Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration. Br J Ophthalmol, 1980;64:766-9.
16. Denis J, Thenault-Giono S, Ray-Cohen ML, Tournoux A, Pouliquen Y. Traitement de l'herpès oculaire en doubleinsu: Vira A et acyclovir. Bull Soc Ophtalmol Fr, 1983;83:25-9.
17. Hoang-Xuan T, Frot P, Denis J, Pouliquen Y. Aciclovir et trifluorothymidine dans la kérato-uvéite herpétique. Une étude comparative en clinique humaine. Indication de la corticothérapie. J Fr Ophtalmol, 1984;7:125-31.
18. Colin J, Hoh HB, Easty DL, Herbort CP, Resnikoff S, Rigal D et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea, 1997;16:393-9.
19. Hoh HB, Hurley C, Claoue C, Viswalingham M, Easty DL, Goldschmidt P et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol, 1996;80:140-3.
20. Castela N, Vermerie N, Chast F, Sauvageon-Martre H, Denis J, Godard V et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. J Ocul Pharmacol, 1994;10:439-51.
21. Kaufman HE, Varnell ED, Thompson HW. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Arch Ophthalmol, 1998;116:777-80.
22. Panda A, Das GK, Khokhar S, Rao V. Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. Can J Ophthalmol, 1995;30:256-8.
23. Power WJ, Benedict-Smith A, Hillery M, Brady K, Collum LM. Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration. Br J Ophthalmol, 1991;75:649-51.
24. Maudgal PC, De Clercq E. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. Curr Eye Res, 1991;10 Suppl: 193-9:193-9.
25. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol, 1997;115:733-7.
26. Labetoulle M, Goujard C, Frau E, Offret H, Delfraissy JF. Cidofovir ocular toxicity is related to previous ocular history. AIDS, 2000;14:622-3.
27. Snoeck R, De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr Opin Investig Drugs, 2002;3:1561-6.
28. Sacks SL, Shafran SD, Diaz-Mitoma F, Trottier S, Sibbald RG, Hughes A et al. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother, 1998;42:2996-9.
29. Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol, 1997;133:987-90.
30. Hillenkamp J, Reinhard T, Ross RS, Bohringer D, Cartsburg O, Roggendorf M et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology, 2002;109:845-50.
31. Hillenkamp J, Reinhard T, Ross RS, Bohringer D, Cartsburg O, Roggendorf M et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol, 2001;119:1487-91.
32. Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci, 1999;40:378-84.
33. Minkovitz JB, Pepose JS. Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. Cornea, 1995;14:326-30.
34. Colin J, Chastel C, Renard G, Cantell K. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir. Am J Ophthalmol, 1983;95:346-8.
35. Collum LM, McGettrick P, Akhtar J, Lavin J, Rees PJ. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol, 1986;70:435-8.
36. Schwartz GS, Holland EJ. Oral acyclovir for the management of herpes simplex virus keratitis in children. Ophthalmology, 2000;107:278-82.
37. Kaufman HE. Treatment of viral diseases of the cornea and external eye. Prog Retin Eye Res, 2000;19:69-85.
38. The Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. Arch Ophthalmol, 1997;115:703-12.
39. Wilhelmus KR, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology, 1994;101:1883-95.
40. Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB etal. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology, 1994;101:1871-82.
41. Hung SO, Patterson A, Rees PJ. Pharmakokinetics of oral aciclovir (Zovirax) in the eye. Br J Ophthalmol, 1984;68:192-5.
42. Teich SA, Cheung TW, Friedman AH. Systemic antiviral drugs used in ophthalmology. Surv Ophthalmol, 1992;37:19-53.
43. Porter SM, Patterson A, Kho P. A comparison of local and systemic acyclovir in the management of herpetic disciform keratitis. Br J Ophthalmol, 1990;74:283-5.
44. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet, 1996;31:1-8.
45. Loutsch JM, Sainz B Jr, Marquart ME, Zheng X, Kesavan P, Higaki S et al. Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. Antimicrob Agents Chemother, 2001;45:2044-53.
46. Tyring S, Engst R, Corriveau C, Robillard N, Trottier S, Van Slycken S et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol, 2001;85:576-81.
47. Vajpayee RB, Dhakal BP, Gupta SK, Sachdev MS, Satpathy G, Honavar SG et al. Evaluation of topical 0.03% flurbiprofen drops in the treatment of herpetic stromal keratitis. Aust N Z J Ophthalmol, 1996;24:131-5.
48. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol, 1999;237:435-8.
49. Zheng M, Deshpande S, Lee S, Ferrara N, Rouse BT. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol, 2001;75:9828-35.
50. Primbs GB, Casey R, Wamser K, Snyder WJ, Crean DH. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg Lasers, 1998;29:832-8.
51. Muraine M, Descargues G, Franck O, Villeroy F, Toubeau D, Menguy E et al. La greffe de membrane amniotique dans les pathologies oculaires de surface. J Fr Ophtalmol, 2001;24:798-812.
52. Kim JS, Kim JC, Hahn TW, Park WC. Amniotic membrane transplantation in infectious corneal ulcer. Cornea, 2001;20:720-6.
53. Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol, 2000;84:826-33.
54. Kruse FE, Rohrschneider K, Volcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology, 1999;106:1504-10.
55. Touhami A, Grueterich M, Tseng SC. The role of NGF signaling in human limbal epithelium expanded by amniotic membrane culture. Invest Ophthalmol Vis Sci, 2002;43:987-94.
56. Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology, 2000;107:1347-51.
57. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med, 1998;338:1174-80.
58. Cellini M, Baldi A, Caramazza N, De Felice GP, Gazzaniga A. Epidermal growth factor in the topical treatment of herpetic corneal ulcers. Ophthalmologica, 1994;208:37-40.
59. Hill JM, Garza HH Jr, Helmy MF, Cook SD, Osborne PA, Johnson EM Jr et al. Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits. J Neurovirol, 1997;3:206-11.
60. Ventura LM, Dix RD. Viability of herpes simplex virus type 1 on the applanation tonometer. Am J Ophthalmol, 1987;103:48-52.
61. Bardell D. Studies on the survival and inactivation of herpes simplex virus type 1 on coins. Microbios, 1994;77:161-6.
62. Hygiène et prise en charge des dispositifs médicaux en consultation d'ophtalmologie. In: Centre de coordination de la lutte contre les infections nosocomiales de l'interrégion Paris-Nord. Guide des bonnes pratiques. Institut biomédical des cordeliers (Paris), 2000.
63. Agence Nationale d'Accréditation et d'Évaluation en Santé. Prise en charge de l'herpès cutanéomuqueux chez le sujet immunocompétent (manifestations oculaires exclues). Conférence de consensus l'Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). Arch Pediatr, 2002;9:744-54.
64. Colin J, Robinet A, Malet F. Traitement préventif des kératites herpétiques par l'acyclovir en comprimés. J Fr Ophtalmol, 1993;16:6-9.
65. Simon AL, Pavan-Langston D. Long-term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts. Ophthalmology, 1996;103:1399-404; discussion 1404.
66. Langston DP. Oral acyclovir suppresses recurrent epithelial and stromal herpes simplex. Arch Ophthalmol, 1999;117:391-2.
67. Rodriguez A, Power WJ, Neves RA, Foster CS. Recurrence rate of herpetic uveitis in patients on long-term oral acyclovir. Doc Ophthalmol, 1995;90:331-40.
68. The Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med, 1998;339:300-6.
69. The Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol, 2000;118:1030-6.
70. Harding SP, Rigal D, Sharma MS, Natha S, Sarapa N, Weller S. Superior intraocular penetration of aciclovir after valaciclovir in comparison with oral aciclovir. 38th Interdisciplinary Conference on Antimicrobial Chemotherapy. San Diego (USA), October 1998 Abstract A-45.
71. Wu X, Chen X. Acyclovir for the treatment and prevention of recurrent infectious herpes simplex keratitis. Chin Med J, 2002;115:1569-72.
72. Blatt AN, Laycock KA, Brady RH, Traynor P, Krogstad DJ, Pepose JS. Prophylactic acyclovir effectively reduces herpes simplex virus type 1 reactivation after exposure of latently infected mice to ultraviolet B. Invest Ophthalmol Vis Sci, 1993;34:3459-65.
73. Goldberg LH, Kaufman R, Kurtz TO, Conant MA, Eron U, Batenhorst RL et al. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch Dermatol, 1993;129:582-7.
74. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol, 2003;121:108-12.
75. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol, 2002;133:401-3.
76. Morales J, Shihab ZM, Brown SM, Hodges MR. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol, 2001;132:114-6.
77. Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol, 2001;85:1008-9.
78. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol, 1999;127:602-4.
79. Kaufman HE, Varnell ED, Toshida H, Kanai A, Thompson HW, Bazan NG. Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. Am J Ophthalmol, 2001;131:643-6.
80. Hill JM, Maggioncalda JB, Garza HH Jr, Su YH, Fraser NW, Block TM. In vivo epinephrine reactivation of ocular herpes simplex virus type 1 in the rabbit is correlated to a 370-base-pair region located between the promoter and the 5′ end of the 2.0 kilobase latency-associated transcript. J Virol, 1996;70:7270-4.
81. Kaufman HE, Varnell ED, Gebhardt BM, Thompson HW, Hill JM. Propranolo suppression of ocular HSV-1 recurrence and associated corneal lesions following spontaneous reactivation in the rabbit Curr Eye Res, 1996;15:680-4.
82. Pepose JS, Laycock KA, Miller JK, Chansue E, Lenze EJ, Gans LA et al. Reactivation of latent herpes simplex virus excimer laser photokeratectomy. Am J Ophthalmol, 1992;114:45-50.
83. Epstein SP, Fisher EM, Sternberg GJ, Franklin W, Gordon R, Ho JJ et al. Recurrent ocular herpes simplex keratitis following excimer laser photorefractive keratectomy in a rabbit model CLAO J, 2001;27:94-9.
84. Beyer CF, Arens MQ, Hill GA, Rose BT, Beyer LR, Schanzlin DJ. Oral acyclovir reduces the incidence of recurrent herpes simplex keratitis in rabbits after penetrating keratoplasty. Arch Ophthalmol, 1989;107:1200-5.
85. Asbell PA. Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy. Trans Am Ophthalmol Soc, 2000;98:285-303.
86. Dhaliwal DK, Romanowski EG, Yates KA, Hu D, Mah FS, Fish DN et al. Valacyclovir inhibition of recovery of ocular herpes simplex virus type 1 after experimental reactivation by laser in situ keratomileusis. J Cataract Refract Surg, 2001;27:1288-93.
87. Schwab IR. Oral acyclovir in the management of herpes simplex ocular infections. Ophthalmology, 1988;95:423-30.
88. Foster CS, Barney NP. Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis. Doc Ophthalmol, 1992;80:363-9.
89. Barney NP, Foster CS. A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea, 1994;13:232-6.
90. Tambasco FP, Cohen EJ, Nguyen LH, Rapuano CJ, Laibson PR. Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol, 1999;117:445-9.
91. Sundmacher R, Wolff M. Four years experience with triple procedures in herpes-afflicted eyes. Ger J Ophthalmol, 1993;2:65-9.
92. Jarade EF, Tabbara KF. Laser in situ keratomileusis in eyes with inactive herpetic keratitis. Am J Ophthalmol, 2001;132:779-80.
93. Pepose JS, Leib DA, Stuart M, Easty DL. Herpes simplex virus diseases: anterior segment of the eye. In: Ocular infection and immunity, Pepose JS, Holland GN, Wilhelmus KR. Mosby (St Louis) 1996;71:p. 905-932.
94. Sawtell NM, Thompson RL. Rapid in vivo reactivation of herpes simplex virus in latenly induced murine ganglionnic neurons after transient hyperthermia. J Virol, 1992;66:2150-6.
95. Sawtell NM, Bernstein DI, Stanberry LR. A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 in vivo reactivation in the mouse trigeminal ganglia. J Infect Dis, 1999;1 80:821-3.
96. Labetoulle M, Maillet S, Efstathiou S, Dezelee S, Frau E, Lafay F. HSV1 latency sites after inoculation in the lip: assessment of their localization and connections to the eye. Invest Ophthalmol Vis Sci, 2003;44:217-25.
97. Sawtell NM. The probabillity of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol, 1998;72:6888-92.
98. Thackray AM, Field HJ. The effects of antiviral therapy on the distribution of herpes simplex virus type 1 to ganglionic neurons and its consequences during, immediately following and several months after treatment [In Process Citation]. J Gen Virol, 2000;81:2385-96.
99. LeBlanc RA, Pesnicak L, Godleski M, Straus SE. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. J Infect Dis, 1999;180:594-9.
100. Nahmias AJ, Roizman B. Infection with herpes simplex viruses I and II. Part III. N Engl J Med, 1973;289:781.
101. Pavan-Langston D. Viral disease of the cornea and external eye. In: "Albert DA, Jakobiec FA, Principles and practice of ophthalmology. Clinical practice" WB Saunders Company, Philadelphia, 1994;6:117-61.
102. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine, 1999;17:1681-9.
103. Kaufman HE, Varnell ED, Wright GE, Xu H, Gebhardt BM, Thompson HW. Effect of 9-(4-hydroxybutyl)-N2-phenylguanine (HBPG), a thymidine kinase inhibitor, on clinical recurrences of ocular herpetic keratitis in squirrel monkeys. Antiviral Res, 1996;33:65-72.